Mainstay Medical Holdings plc announced the publication of a pooled analysis of three different clinical studies that evaluated the safety and efficacy of ReActiv8 therapy after two years in patients of various ages. The analysis, published in Regional Anesthesia & Pain Medicine, included 261 patients across the ReActiv8-B, ReActiv8-C, and PMCF studies, with the results demonstrating that age is not a factor when utilizing ReActiv8 to treat intractable mechanical chronic low back pain patients with multifidus dysfunction. There were no statistically significant or clinically meaningful differences between the groups in the magnitude or durability of response across pain, disability, or health-related quality of life measures.

Patients aged 56-82 (n=65): Percentage of patients with >50% pain reduction: 62%; Mean Oswestry Disability Index (ODI) Score: 23.4; Mean EQ-5D Quality of Life Score: 0.763. Patients aged 56 and below (n=196): ercentage of patients with >50% pain reduction: 66%; Mean Oswestry Disability Index (ODI) Score: 20.8; Mean EQ-5D Quality of Life Score: 0.770.